Biofrontera AG Profit Margin 2017-2021 | BFRA

Current and historical gross margin, operating margin and net profit margin for Biofrontera AG (BFRA) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Biofrontera AG net profit margin as of June 30, 2021 is -59.7%.
Biofrontera AG Annual Profit Margins
Biofrontera AG Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.150B $0.036B
Biofrontera AG is a biopharmaceutical company. It engaged in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases. The company's products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions which can sometimes lead to skin cancer as well as the treatment of certain forms of basal cell carcinoma in the European Union. Biofrontera AG is based in Leverkusen, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00